Long-term follow-up from the phase 1/2a PLX120-03 trial indicates that plixorafenib (PLX8394/FORE8394) can sustain durable responses in BRAF-altered primary central nervous system tumors. The presented data report high objective response rates and progression-free survival durability with no evidence of cumulative adverse effects over longer treatment exposure. In the prespecified MAPK inhibitor–naïve BRAF V600E subgroup (N=9), the objective response rate reached 67% with all six responses partial. Across high-grade glioma (n=5) and low-grade glioma or glioneuronal tumors (n=4), the reported ORR was 80% and 50%, respectively, with 12- and 24-month PFS rates of 56% and 33%. Investigators also described prolonged treatment durations, with some patients remaining on therapy for years and experiencing additional prolonged responses after progression when later treated with other MAPK inhibitors. The single-agent design targets BRAF V600 monomers while disrupting mutant BRAF dimers to reduce paradoxical pathway activation. The results may strengthen the clinical rationale for single-agent BRAF pathway inhibition in CNS tumors where prior targeted strategies often face constrained tolerability and biomarker complexity.
Get the Daily Brief